A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data-Reference-Cited by-同舟云学术

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data

Published:2017-09-30 Issue:1 Volume:17 Page:
ISSN:1471-2334
Container-title:BMC Infectious Diseases
language:en
Short-container-title:BMC Infect Dis

Author:

Capetti Amedeo F.,Cossu Maria Vittoria,Orofino Giancarlo,Sterrantino Gaetana,Cenderello Giovanni,De Socio Giuseppe V.,Cattelan Anna Maria,Soria Alessandro,Rusconi Stefano,Riccardi Niccolò,Baldin Gian Maria,Niero Fosca P.,Barbarini Giorgio,Rizzardini Giuliano

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases

Link

http://link.springer.com/content/pdf/10.1186/s12879-017-2755-4.pdf

Reference11 articles.

1. Capetti AF, Sterrantino G, Cossu MV, Cenderello G, Cattelan AM, De Socio GV, et al. Correction: Correction: Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort. Antivir Ther. 2017;22(3):273–5. doi: 10.3851/IMP3109 . Epub 2016 Nov 28

2. Dual Therapy With Boosted Darunavir + Dolutegravir (Dualis) https://clinicaltrials.gov/ct2/show/NCT02486133 Accessed 4 April, 2017.

3. Tashima KT, Mollan KR, Na L, Gandhi RT, Klingman KL, Fichtenbaum CJ, et al. Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race–ethnicity determine the degree of regimen complexity. HIV Clin Trials. 2015;16(4):147–56.

4. Tashima KT, Smeaton LM, Fichtenbaum CJ, Andrade A, Eron JJ, Gandhi RT, et al. HIV salvage therapy does not require nucleoside reverse transcriptase inhibitors: a randomized trial. Ann Intern Med. 2015;163(12):908–17.

5. Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, et al. A randomized, open-label trial to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1 infected adults. J Acquir Immune Defic Syndr. 2017;74(2):193–200.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation;Viruses;2024-08-30

2. Effectiveness and Tolerability of Dual Therapy with Dolutegravir Plus Darunavir/cobicistat in Treatment-Experienced Patients with HIV: A 144-Week Follow-Up;Infection & Chemotherapy;2024

3. High drug loading solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsions for the dual drug delivery of the HIV drugs darunavir and ritonavir;JCIS Open;2023-10

4. GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants;Science Advances;2023-07-14

5. Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007–2018;International Journal of Antimicrobial Agents;2023-01